{"id":594460,"date":"2026-09-09T00:46:09","date_gmt":"2026-09-09T00:46:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/594460\/"},"modified":"2026-09-09T00:46:09","modified_gmt":"2026-09-09T00:46:09","slug":"forget-csl-shares-3-asx-healthcare-stocks-with-bigger-upside","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/594460\/","title":{"rendered":"Forget CSL shares. 3 ASX healthcare stocks with bigger upside"},"content":{"rendered":"

CSL Ltd (ASX: CSL<\/a>) shares have surged 32% over the past month after stronger-than-expected plasma product sales. But with the rally potentially priced in, analysts see better value elsewhere in healthcare.<\/p>\n

CSL shares are now trading around $174.80, above the average broker price target. Macquarie has a neutral rating and a target of just over $133, while UBS is more bullish at $181 and Morgan Stanley has a $172 target.<\/p>\n

So, where could investors look instead?<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

Pro Medicus Ltd (ASX: PME<\/a>)<\/p>\n

Pro Medicus shares have endured a brutal 12 months, falling around 43%. But unlike CSL shares, the sell-off hasn’t been accompanied by a deterioration in the company’s underlying growth.<\/p>\n

FY26 revenue increased 22.9% to $261.7 million, while underlying EBIT and NPAT<\/a> climbed 24.4% and 24.1%, respectively.<\/p>\n

Its Visage imaging software is already used by major healthcare systems across North America, yet management estimates it has captured only around 11% of the US market. That leaves plenty of room to grow.<\/p>\n

Citi has a buy rating and $225 target, implying around 33% upside. Bell Potter is also bullish, with a $226 target, while Barrenjoey has a $210 target. JPMorgan is more cautious with a hold rating and $211 target.<\/p>\n

ResMed shares have bounced around 25% from their multi-year low in June, but remain down roughly 25% over 12 months. That’s a steeper decline than CSL shares, which still fell 18% over the same period despite their recent rebound.<\/p>\n

The sell-off reflected broader pressure on healthcare shares<\/a>, alongside macroeconomic uncertainty, inflation and cost-of-living concerns. A soft third-quarter update in May added to the pressure.<\/p>\n

However, ResMed subsequently delivered a stronger fourth-quarter result, helping restore investor confidence.<\/p>\n

The sleep-disorder specialist continues to deliver healthy revenue growth, expanding margins and strong free cash flow<\/a>. Its third-quarter revenue rose 11% to US$1.4 billion, driven by demand for sleep devices, masks and accessories.<\/p>\n

Most brokers rate ResMed shares buy or strong buy. The highest price target of $45.90 implies potential upside of around 46%.<\/p>\n

Telix Pharmaceuticals Ltd (ASX: TLX<\/a>)<\/p>\n

Telix Pharmaceuticals operates in a highly specialised healthcare niche: radiopharmaceuticals. Its products combine radioactive isotopes with targeted diagnostics and therapies, helping doctors detect and treat diseases such as cancer with greater precision.<\/p>\n

That creates significant barriers to entry and gives Telix shares an interesting growth profile that differs from CSL shares.<\/p>\n

In August, Telix reported a 22% year-on-year increase in revenue to US$477 million, putting it towards the upper end of its FY26 guidance.<\/a><\/p>\n

Brokers are increasingly bullish, with 13 of 16 analysts rating Telix shares buy or strong buy. The average $25.29 target implies roughly 53% upside from $16.50, while the most bullish forecast points to more than 85% potential upside.<\/p>\n

For investors looking beyond CSL shares, these three healthcare names could offer considerably more upside.<\/p>\n","protected":false},"excerpt":{"rendered":"CSL Ltd (ASX: CSL) shares have surged 32% over the past month after stronger-than-expected plasma product sales. But…\n","protected":false},"author":2,"featured_media":594461,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[134,527,111,139,69],"class_list":["post-594460","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/594460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=594460"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/594460\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/594461"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=594460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=594460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=594460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}